Core Viewpoint - Nutriband Inc. has filed a provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology aimed at preventing the misuse of opioids and stimulants [1][2]. Group 1: Patent Application and Technology - The provisional patent application focuses on improved aversive formulations and coating methods to strengthen the abuse deterrent properties of the AVERSA™ technology [2]. - If converted to a non-provisional patent, it could extend patent protection for products utilizing AVERSA™ for 20 years from the non-provisional filing date [2]. - The AVERSA™ technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries, including the U.S., Europe, Japan, and China [3]. Group 2: Technology Applications and Benefits - AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, such as opioids and stimulants [4][5]. - This technology aims to improve the safety profile of transdermal drugs while ensuring accessibility for patients who genuinely need them [4][5]. Group 3: Company Overview - Nutriband Inc. is primarily focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [6].

Core Points - Nutriband Inc. will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on October 8, 2025, at 15:00 Eastern Standard Time, featuring a Q&A session [1] - The presentation will be available for viewing via a video webcast on Channelchek and will be archived for 90 days [3] - Nutriband is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [5] Company Overview - Nutriband's AVERSA™ technology incorporates aversive agents into transdermal patches to prevent drug abuse, ensuring safety while maintaining accessibility for patients in need [4] - The technology is protected by a broad intellectual property portfolio with patents granted in multiple countries, including the United States, Europe, and China [4] - The company is primarily engaged in the development of transdermal pharmaceutical products, aiming to address the issues of drug abuse and misuse [5] Event Details - Attendees can register for the virtual conference at no cost, and qualified investors can schedule one-on-one meetings with company management [2] - The event is organized by Noble Capital Markets, a full-service investment bank with a strong research team and a history of raising billions for companies [7] - Channelchek, launched by Noble, provides free access to institutional-quality research for emerging growth companies [8]

Core Viewpoint - MediWound reported a quarterly loss of $1.23 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.55, marking an earnings surprise of -123.64% [1] - The company posted revenues of $5.71 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.89% and showing growth from $5.06 million a year ago [2] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.64 on revenues of $6.68 million, and for the current fiscal year, it is -$1.99 on revenues of $23.97 million [7] Stock Performance - MediWound shares have increased by approximately 5.3% since the beginning of the year, compared to a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Drugs industry is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - ARS Pharmaceuticals, Inc. reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, and compared to a loss of $0.13 per share a year ago, indicating a significant decline [1] - The company posted revenues of $15.72 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.98%, and showing a substantial increase from year-ago revenues of $0.5 million [2] - Over the last four quarters, ARS Pharmaceuticals has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates two times [2] Stock Performance - ARS Pharmaceuticals shares have increased approximately 57.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 9.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $29.98 million, and for the current fiscal year, it is -$1.44 on revenues of $84.04 million [7] Industry Outlook - The Medical - Drugs industry, to which ARS Pharmaceuticals belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can materially impact stock performance [5][8]

Company Performance - Assertio reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.04 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $29.22 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.55%, but down from $31.13 million in the same quarter last year [2] - Over the last four quarters, Assertio has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - Assertio shares have declined approximately 16.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $31.2 million, and for the current fiscal year, it is -$0.27 on revenues of $117.81 million [7] Industry Context - The Medical - Drugs industry, to which Assertio belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Assertio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Core Viewpoint - Nutriband Inc. CEO Gareth Sheridan will temporarily step aside to participate in the Irish Presidential Election, with Chairman Serguei Melnik taking over as interim CEO during this period [1][2][3] Company Leadership Transition - Gareth Sheridan will step down for three months, with the nomination hearings and election occurring in September and October [1] - Serguei Melnik, co-founder and Chairman, will assume CEO responsibilities and guide the company towards its NDA filing target in 2026 [2] Strategic Focus - Melnik, with over 20 years of experience in capital markets, will continue to execute the company's strategic development and focus on enhancing shareholder value [2] - Sheridan emphasized the strength of the company's team as its core asset and expressed confidence in meeting planned targets during his absence [3] Product Development - Nutriband's lead product, AVERSA Fentanyl, has received FDA approval for a meeting request, positioning it as a potential first-of-its-kind abuse-deterrent opioid patch [4] - AVERSA Fentanyl is projected to achieve peak annual US sales between $80 million and $200 million, with plans to expand into major global markets [4] Intellectual Property - The AVERSA technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including the US, Europe, and China [5] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with AVERSA technology designed to prevent the abuse and accidental exposure of drugs with abuse potential [6]

Core Viewpoint - The FDA has granted Nutriband a Type C Meeting to discuss the Chemistry, Manufacturing, and Controls plans for its AVERSA™ FENTANYL product, which aims to provide an abuse-deterrent transdermal system for fentanyl [1][2]. Group 1: Product Development - Nutriband is collaborating with Kindeva to develop AVERSA™ FENTANYL, integrating Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch [1][2]. - The AVERSA™ technology incorporates aversive agents into transdermal patches to prevent abuse, misuse, and accidental exposure of drugs with abuse potential, particularly opioids [3][6]. Group 2: Market Potential - AVERSA FENTANYL could be the first abuse-deterrent opioid patch, with potential peak annual sales in the U.S. estimated between $80 million and $200 million [4]. - The company aims to address the global unmet medical need for effective pain management by making AVERSA FENTANYL available in major medical markets worldwide [4]. Group 3: Intellectual Property - The AVERSA™ abuse-deterrent technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries, including the U.S., Europe, Japan, and China [5][6]. Group 4: Company Overview - Nutriband is focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being the abuse-deterrent fentanyl patch [7].

Group 1: Financial Performance - Aclaris Therapeutics reported a quarterly loss of $0.13 per share, which is in line with the Zacks Consensus Estimate and an improvement from a loss of $0.15 per share a year ago [1] - The company posted revenues of $1.78 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 14.42%, but down from $2.77 million year-over-year [2] - Aclaris has exceeded consensus EPS estimates two times over the last four quarters [1][2] Group 2: Stock Performance and Outlook - Aclaris shares have declined approximately 37.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at -$0.14 for the coming quarter and -$0.54 for the current fiscal year [4][7] - The estimate revisions trend for Aclaris was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 3: Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aclaris's stock performance [5]

Core Insights - Nutriband Inc. has received a patent grant in Macao for its AVERSA™ abuse deterrent transdermal technology, enhancing its intellectual property portfolio [1][2][3] - The AVERSA™ technology aims to prevent the abuse and misuse of drugs, particularly opioids, while ensuring accessibility for patients in need [4][6] - The company is collaborating with Kindeva Drug Delivery to develop AVERSA™ Fentanyl, which could potentially achieve peak annual US sales between $80 million and $200 million [5][6] Intellectual Property - The patent J/9010 was granted on February 11, 2025, and is part of a broader international portfolio covering 46 countries, including major markets like the US, Europe, and China [2][3] - Macao's patent system operates independently from mainland China's, providing a unique advantage for Nutriband's technology [2] Product Development - AVERSA™ technology incorporates aversive agents into transdermal patches to mitigate risks associated with drug abuse, including accidental exposure [4][6] - The lead product under development is an abuse-deterrent fentanyl patch, which is designed to be the first of its kind in the market [5][6] Market Potential - The AVERSA™ Fentanyl patch is positioned to address significant market needs in opioid management, with a substantial projected sales range indicating strong market interest [6]

Core Insights - Nutriband Inc. has signed an Associate Partnership agreement with Charlotte FC to enhance brand visibility, particularly for its AI Tape product manufactured locally in Charlotte [1][2] - The partnership aims to promote Nutriband's AVERSA technology, which is positioned as a potential breakthrough in abuse deterrent patches for chronic pain management [3][4] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch utilizing AVERSA technology [4] - AVERSA technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be integrated into any transdermal patch [4]